Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05469893 · ClinicalTrials.gov registry record · Phase 2

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

A Phase 2 study of Multiple Myeloma and Smoldering Multiple Myeloma, sponsored by Irene Ghobrial, MD.

Recruiting
Registry status
Phase 2
Development phase
52
Enrollment target
3
Study locations

NCT05469893 is a Phase 2 study of Multiple Myeloma and Smoldering Multiple Myeloma that is actively recruiting participants, run by Irene Ghobrial, MD. The registered enrollment target is 52 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05469893, a Phase 2 study of Multiple Myeloma and Smoldering Multiple Myeloma, is actively recruiting participants, sponsored by Irene Ghobrial, MD.

RECRUITING
Registry status
Phase 2
Development phase
52 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma. People with smoldering multiple myeloma (SMM) usually do not have symptoms but are at risk for progressing to active multiple myeloma (MM). Multiple Myeloma is a cancer of the plasma cells, which are an important part of the immune system. Patients with active multiple myeloma generally require treatment but there are currently no approved therapies for smoldering multiple myeloma. The names of the study drugs involved in this study are: * Teclistamab * Lenalidomide (also called Revlimid) * Dexamethasone (also called Decadron)

Conditions Studied

Multiple Myeloma Smoldering Multiple Myeloma High-risk Smoldering Multiple Myeloma

Interventions

  • DRUG Teclistamab
  • DRUG Dexamethasone
  • DRUG Lenalidomide

Study Locations (3)

Colorado

  • Colorado Blood Cancer Institute - Denver

Massachusetts

  • Dana Farber Cancer Institute - Boston

Oregon

  • Oregon Health & Science University - Portland

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2022-08-10
Est. Completion 2030-07-31
Phase Phase 2

Sponsor

Irene Ghobrial, MD

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05469893

The ClinicalTrials.gov registry entry for NCT05469893 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower). The listed sponsor is Irene Ghobrial, MD, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Teclistamab is the first listed.

NCT05469893 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Colorado, Massachusetts, Oregon.

Frequently Asked Questions

What is clinical trial NCT05469893 about?

NCT05469893 is a clinical study titled "Immuno-PRISM (PRecision Intervention Smoldering Myeloma)". The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma. People with smoldering multiple myeloma (SMM) usually do not have symptoms but are at risk for progressi...

What is the current status of trial NCT05469893?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2022-08-10. Estimated completion is 2030-07-31.

What conditions does trial NCT05469893 study?

This clinical trial studies the following conditions: Multiple Myeloma, Smoldering Multiple Myeloma, High-risk Smoldering Multiple Myeloma.

What interventions are being tested in trial NCT05469893?

The interventions under investigation include: Teclistamab (DRUG), Dexamethasone (DRUG), Lenalidomide (DRUG).

Who is sponsoring clinical trial NCT05469893?

This trial is sponsored by Irene Ghobrial, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05469893 being conducted?

This trial has 3 study locations across Colorado, Massachusetts, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Smoldering Multiple Myeloma

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.